-
11:00:55 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

ANEB Stock News

06/23/22 4:00 PM
Nasdaq : ANEB
clinical triallow float
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder, anticipates releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. Anebulo Pharmaceuticals, Inc. is a clinical-stage...
RHEA-AI
neutral
05/11/22 9:00 AM
Nasdaq : ANEB
earningslow float
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, today announced financial results for the three months ended March 31, 2022 and recent updates. Completed enrollment of all 60 subjects in Part A of an ongoing Phase 2...
RHEA-AI
neutral
04/01/22 7:00 AM
Nasdaq : ANEB
clinical triallow float
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder, today announced the dosing of more than half of the 60 subjects planned in Part A of an ongoing Phase 2 clinical trial at the Centre for Human Drug Research in the...
RHEA-AI
neutral
02/11/22 8:00 AM
Nasdaq, NYSE : ANEB, AMAM, OIIM
earningslow float
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, today announced financial results for the three months ended December 31, 2021 and recent updates. Mr. Allen started his career in the lab at Gilead Sciences working on...
RHEA-AI
neutral
01/06/22 7:00 AM
Nasdaq : ANEB
managementlow float
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately. In this position, Mr. Anderson will report...
RHEA-AI
neutral
01/04/22 7:00 AM
Nasdaq, NYSE : ANEB, AMAM
low float
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’ s Board of Directors, effective February 1 st, 2022. Mr. Allen succeeds Daniel Schneeberger, MD, who...
RHEA-AI
positive
01/03/22 7:00 AM
Nasdaq : ANEB
clinical triallow float
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid...
RHEA-AI
neutral
12/22/21 4:05 PM
Nasdaq : TNYA, EOLS, ANEB
managementlow float
Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture
Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. Her previous experience includes over...
RHEA-AI
neutral